Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

Autor: Lu, Shun *, Zhou, Jianying **, Jian, Hong, Wu, Lin, Cheng, Ying, Fan, Yun, Fang, Jian, Chen, Gongyan, Zhang, Zhihong, Lv, Dongqing, Jiang, Liyan, Wu, Rong, Jin, Xiangming, Zhang, Xiaodong, Zhang, Junhong, Xie, Conghua, Sun, Gengyun, Huang, Dongning, Cui, Jiuwei, Guo, Renhua, Han, Zhigang, Chen, Zhendong, Liang, Jin, Zhuang, Wu, Hu, Xingsheng, Zang, Aimin, Zhang, Yi, Cang, Shundong, Lan, Yuanbo, Chen, Xi, Liu, Laiyu, Li, Xingya, Chen, Jun, Ma, Rui, Guo, Yanzhen, Sun, Ping, Tian, Panwen, Pan, Yueyin, Liu, Zhe, Cao, Peiguo, Ding, Lieming, Wang, Yang, Yuan, Xiaobin, Wu, Pengxiang
Zdroj: In The Lancet Respiratory Medicine October 2023 11(10):905-915
Databáze: ScienceDirect